Lineage Cell Therapeutics (STU:BT3) Total Assets : €87.03 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Lineage Cell Therapeutics Total Assets?

Lineage Cell Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was €87.03 Mil.

During the past 12 months, Lineage Cell Therapeutics's average Total Assets Growth Rate was -1.40% per year. During the past 3 years, the average Total Assets Growth Rate was -0.40% per year. During the past 5 years, the average Total Assets Growth Rate was -2.60% per year. During the past 10 years, the average Total Assets Growth Rate was 3.20% per year.

During the past 13 years, Lineage Cell Therapeutics's highest 3-Year average Total Assets Growth Rate was 394.50%. The lowest was -54.20%. And the median was 1.30%.

Total Assets is connected with ROA %. Lineage Cell Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -11.98%. Total Assets is also linked to Revenue through Asset Turnover. Lineage Cell Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.04.

Lineage Cell Therapeutics Total Assets Historical Data

The historical data trend for Lineage Cell Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Total Assets Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

112.93

88.73

154.47

116.74

92.63

Lineage Cell Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															99.47	92.63	99.80	95.50	87.03

Lineage Cell Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lineage Cell Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	56.875	+	35.759
	=	92.63

Lineage Cell Therapeutics's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	58.379	+	28.652
	=	87.03

Lineage Cell Therapeutics (STU:BT3) Total Assets Explanation

Total Assets is connected with ROA %.

Lineage Cell Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-10.936	/	( (95.503	+	87.031)	/ 2 )
	=	-10.936	/	91.267
	=	-11.98 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lineage Cell Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	3.405	/	( (95.503	+	87.031)	/ 2 )
=	3.405	/	91.267
=	0.04

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lineage Cell Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (STU:BT3) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

LCTX:USA LCTX:Israel BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics Headlines

No Headlines